FDA OKs Cystic Fibrosis Drug Orkambi for Younger Patients FDA OKs Cystic Fibrosis Drug Orkambi for Younger Patients

The lumacaftor/ivacaftor combination drug is now approved for children aged 6 to 11 years with two copies of the F508del mutation in the CTFR gene.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news